Effect of Probiotics on Amino Acid Absorption

NCT05752266 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-11-29

No results posted yet for this study

Summary

The goal of this clinical trial is to test effects of consuming probiotics in healthy adults. The main question it aims to answer is:

• Do consuming probiotics affect a healthy adult's ability to absorb amino acids from plant proteins?

Participants will

* Consume one dose of probiotic pills per day after meals for two weeks
* Consume one dose of plant-based plant protein beverage after an overnight fast and collection of one 5 ml fasting blood sample
* Undergo blood draw of 6 more 5 ml blood samples for the next 3 hours after consuming plant-based protein beverage

Conditions

  • Protein Digestion
  • Gastrointestinal Microbiome

Interventions

DIETARY_SUPPLEMENT

AMILI Probiotic pills

AMILI (AMILI Pte Ltd) will analyze stool samples provided by participants, and assign each participant a type of probiotic pill from the 5 different types of probiotic pills commercially available in AMILI retail store.

DIETARY_SUPPLEMENT

Placebo pills

Placebo pills contaning maltodextrin with similar appearance to Probiotic pills will be provided to participants allocated to the Placebo Arm.

Sponsors & Collaborators

  • AMILI Pte. Ltd.

    collaborator UNKNOWN
  • Singapore Institute of Technology

    lead OTHER

Principal Investigators

  • Verena Tan, M.Nutr.Diet · +65 9172 4062

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-27
Primary Completion
2023-07-14
Completion
2024-09-30

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05752266 on ClinicalTrials.gov